Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers

Xenobiotica

Volumn 46, Issue 10, 2016, Pages 896-900

  Jia, Fei Fei ^a,b,c   Tan, Zhi Rong ^a,c   McLeod, Howard L ^a,b   Chen, Yao ^a,c   Ou Yang, Dong Sheng ^a,c   Zhou, Hong Hao ^a,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Drug drug interaction; Healthy subjects; Pharmacokinetics; Quercetin; Transporters

Indexed keywords

CEFPROZIL; QUERCETIN; ANTIINFECTIVE AGENT; ANTIOXIDANT; CEPHALOSPORIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; HAN CHINESE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CLINICAL TRIAL; VOLUNTEER;

ADULT; ANTI-BACTERIAL AGENTS; ANTIOXIDANTS; CEPHALOSPORINS; CROSS-OVER STUDIES; HUMANS; MALE; QUERCETIN; VOLUNTEERS;

EID: 84962517534     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1132792     Document Type: Article

References (27)

1. S.Akanuma, Y.Uchida, S.Ohtsuki,. (2011). Molecular-weight-dependent, anionic-substrate-preferential transport of β-lactam antibiotics via multidrug resistance-associated protein 4. Drug Metab Pharmacokinet 26:602–11
2. P.Anderle, C.U.Nielsen, J.Pinsonneault,. (2006). Genetic variants of the human dipeptide transporter PEPT1. J Pharmacol Exp Ther 316:636–46
3. E.Batard, N.Lecadet, N.Goffinet,. (2015). High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia. Infection 43:681–9
4. K.Bishayee, A.R.Khuda-Bukhsh, S.O.Huh (2015). PLGA-loaded gold-nanoparticles precipitated with quercetin downregulate HDAC-Akt activities controlling proliferation and activate p53-ROS crosstalk to induce apoptosis in hepatocarcinoma cells. Mol Cells 38:518–27
5. A.W.Boots, G.R.Haenen, A.Bast (2008). Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585:325–37
6. I.Cascorbi (2006). Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457–73
7. R.Cermak, S.Wein, S.Wolffram, P.Langguth (2009). Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. Eur J Pharm Sci 38:519–24
8. A.D’Avolio, C.Carcieri, J.Cusato,. (2014). Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother 69:3061–6
9. K.M.Denny Joseph, Muralidhara. (2015). Combined oral supplementation of fish oil and quercetin enhances neuroprotection in a chronic rotenone rat model: relevance to Parkinson’s disease. Neurochem Res 40:894–905
10. E.Diletti, D.Hauschke, V.W.Steinijans (1991). Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29:1–8
11. J.G.Gormaz, S.Quintremil, R.Rodrigo (2015). Cardiovascular disease: a target for the pharmacological effects of quercetin. Curr Top Med Chem 15:1735–42
12. S.A.Heinz, D.A.Henson, M.D.Austin,. (2010). Quercetin supplementation and upper respiratory tract infection: a randomized community clinical trial. Pharmacol Res 62:237–42
13. K.Ito, T.Koresawa, K.Nakano, T.Horie (2004). Mrp2 is involved in benzylpenicillin-induced choleresis. Am J Physiol Gastrointest Liver Physiol 287:G42–9
14. Y.Kato, S.Takahara, S.Kato,. (2008). Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos 36:1088–96
15. J.Kennedy (2005). Herb and supplement use in the US adult population. Clin Ther 27:1847–58
16. Y.Liu, Y.M.Wu, P.Y.Zhang (2015). Protective effects of curcumin and quercetin during benzo(a)pyrene induced lung carcinogenesis in mice. Eur Rev Med Pharmacol Sci 19:1736–43
17. M.Nakakariya, T.Shimada, M.Irokawa,. (2008). Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab Pharmacokinet 23:347–55
18. A.N.Rizwan, G.Burckhardt (2007). Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24:450–70
19. K.Sathirakul, H.Suzuki, K.Yasuda,. (1993). Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. J Pharmacol Exp Ther 265:1301–12
20. I.Tamai, J.Nezu, H.Uchino,. (2000). Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251–60
21. D.Tsai, J.A.Jamal, J.S.Davis,. (2015). Interethnic differences in pharmacokinetics of antibacterials. Clin Pharmacokinet 54:243–60
22. A.Tsuji, T.Terasaki, I.Tamai, K.Takeda (1990). In vivo evidence for carrier-mediated uptake of beta-lactam antibiotics through organic anion transport systems in rat kidney and liver. J Pharmacol Exp Ther 253:315–20
23. Y.Uwai, H.Saito, K.Inui (2002). Rat renal organic anion transporter rOAT1 mediates transport of urinary-excreted cephalosporins, but not of biliary-excreted cefoperazone. Drug Metab Pharmacokinet 17:125–9
24. U.Wenzel, S.Kuntz, S.Diestel, H.Daniel (2002). PEPT1-mediated cefixime uptake into human intestinal epithelial cells is increased by Ca2 + channel blockers. Antimicrob Agents Chemother 46:1375–80
25. C.H.Wu, C.C.Wang, J.Kennedy (2013). The prevalence of herb and dietary supplement use among children and adolescents in the United States: results from the 2007 National Health Interview Survey. Complement Ther Med 21:358–63
26. L.X.Wu, C.X.Guo, W.Q.Chen,. (2012). Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. Br J Clin Pharmacol 73:750–7
27. E.Y.Zhang, D.J.Fu, Y.A.Pak,. (2004). Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: implications for the functional role of Pro586. J Pharmacol Exp Ther 310:437–45